Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial

BACKGROUND: HLX02 is an approved biosimilar of trastuzumab. OBJECTIVE: This study aimed to evaluated the efficacy, safety, and immunogenicity of HLX02 compared with reference trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Binghe, Zhang, Qingyuan, Sun, Tao, Li, Wei, Teng, Yue’e, Hu, Xichun, Bondarenko, Igor, Adamchuk, Hryhoriy, Zhang, Liangming, Trukhin, Dmytro, Wang, Shusen, Zheng, Hong, Tong, Zhongsheng, Shparyk, Yaroslav, Wang, Qingyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084805/
https://www.ncbi.nlm.nih.gov/pubmed/33826080
http://dx.doi.org/10.1007/s40259-021-00475-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084805/
https://www.ncbi.nlm.nih.gov/pubmed/33826080
http://dx.doi.org/10.1007/s40259-021-00475-w

Ejemplares similares